DS
ASPX

David Shaw’s AUSPEX PHARMACEUTICALS INC COM STK (DE) ASPX Stock Holding History

David Shaw’s Portfolio ASPX Stock Details ASPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-21,737
Closed -$1.14M – 4306
2014
Q4 		$1.14M Buy
+21,737
New +$638K ﹤0.01% 2731
2014
Q3 		– Sell
-10,435
Closed -$232K – 4649
2014
Q2 		$232K Buy
+10,435
New +$228K ﹤0.01% 3928

Other funds holding ASPX

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

David Shaw's ASPX Position: Q1 2015 in Review

David Shaw sold out of AUSPEX PHARMACEUTICALS INC COM STK (DE) (ASPX) in Q1 2015, closing a stake of 21,737 shares — an estimated $1.14M sold.

David Shaw first reported a position in ASPX in Q2 2014 and held it in 2 quarters. The position peaked at $1.14M in Q4 2014. 138 funds tracked by Wall St. Rank hold ASPX as of Q1 2015.

  • David Shaw reported no remaining AUSPEX PHARMACEUTICALS INC COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • David Shaw sold 21,737 AUSPEX PHARMACEUTICALS INC COM STK (DE) shares in Q1 2015, an estimated $1.14M.
  • David Shaw first reported a position in AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2014 and held it in 2 quarters.
  • David Shaw's AUSPEX PHARMACEUTICALS INC COM STK (DE) position peaked at $1.14M in Q4 2014.
  • 138 funds tracked by Wall St. Rank held AUSPEX PHARMACEUTICALS INC COM STK (DE) as of Q1 2015.

Based on D.E. Shaw & Co's 13F filing for Q1 2015, filed 15 May 2015.